Mestronaq en es it fr

Mestronaq Brand names, Mestronaq Analogs

Mestronaq Brand Names Mixture

  • Cimicifuga Plex (Caulophyllum Thalictroides + Cimicifuga Racemosa + Copper + Cotton Plant + Estrone + Histamine Dihydrochloride + Hypothalamus + Magnesium Phosphate Dibasic + Pituitary Whole + Platinum + Sepia Officinalis L + Thyroid)
  • Holis 98 (Dioscorea Vilosa + Estrone + Salvia + Saw Palmetto)

Mestronaq Chemical_Formula

C18H22O2

Mestronaq RX_link

No information avaliable

Mestronaq fda sheet

Mestronaq msds (material safety sheet)

Mestronaq MSDS

Mestronaq Synthesis Reference

G. Anner, K. Miescher, and Helv. Chem. Acta. 31, 2173(1948)

Mestronaq Molecular Weight

270.366 g/mol

Mestronaq Melting Point

254.5-256 oC

Mestronaq H2O Solubility

3 g/100mL

Mestronaq State

Solid

Mestronaq LogP

4.067

Mestronaq Dosage Forms

Vaginal cream; Vaginal suppository; Patch; Skin gel; Tablet; IM injectable suspension

Mestronaq Indication

For management of Menopausal and postmenopausal disorders

Mestronaq Pharmacology

Estrone, a synthetically prepared or naturally occurring steroidal estrogen obtained from pregnant equine urine, is the primary circulating estrogen after menopause. Estrone is naturally derived from the peripheral conversion of androstenedione by an aromatase enzyme found in adipose tissues and is converted to estradiol in peripheral tissues. Estropipate is piperazine-stabilized estrone sulfate. Estrone, and estropipate are used to treat abnormalities related to gonadotropin hormone dysfunction, vasomotor symptoms, atrophic vaginitis, and vulvar atrophy associated with menopause, and for the prevention of osteoporosis due to estrogen deficiency.

Mestronaq Absorption

43%

Mestronaq side effects and Toxicity

Symptoms of overdose include nausea and vomiting. Withdrawal bleeding may occur in females.

Mestronaq Patient Information

Mestronaq Organisms Affected

Humans and other mammals